In reply [8]

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2436-2437

  Pignata, Sandro ^a   Perrone, Francesco ^a   Di Maio, Massimo ^a   Gallo, Ciro ^b   De Placido, Sabino ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 33845984230     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.266     Document Type: Letter

References (2)

1. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22:2635-2642, 2004
2. Crawford SM, Paul J, Reed NS, et al: The prognostic significance of the CA125 nadir in patients that achieve a CA125 response. Proc Am Soc Clin Oncol 22:448, 2004 (abstr 5001)